Showing results (571-580 of 734) with videos related to

Sort By:
Pageof 74
British Journal of Haematology|May 4, 2017
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphomaNarendranath Epperla, Anthony Q Pham, Brian L Burnette, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2013
Bowel perforation in intestinal lymphoma: incidence and clinical featuresR Vaidya, T M Habermann, J H Donohue, et al.
Transplantation|October 8, 2020
Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center ExperienceCarla Leal Moreira, M Hasib Sidiqi, Francis K Buadi, et al.
Hematological Oncology|June 11, 2016
FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohortsHervé Ghesquières, Beth R Larrabee, Corinne Haioun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II studyGrzegorz S Nowakowski, Betsy LaPlant, William R Macon, et al.
British Journal of Haematology|March 10, 2026
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypesGeorge A Cholack, Raphael Mwangi, Prokop Vodička, et al.
The Lancet. Haematology|August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialCatherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.
Blood Cancer Journal|August 17, 2023
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphomaZhi-Zhang Yang, Hyo Jin Kim, Hongyan Wu, et al.
Hematological Oncology|January 19, 2021
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyMartin Hutchings, John Radford, Stephen M Ansell, et al.
Blood Cancer Journal|February 18, 2014
Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphomaS M Ansell, L S Hodge, F J Secreto, et al.
Pageof 74